Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that the Medidata Clinical Cloud has been adopted by Nobelpharma to accelerate its efforts to deliver innovative treatments to patients with unmet medical needs.

The Tokyo-based pharmaceutical company is using Medidata’s cloud technology to power a clinical trial on sleep disorders in children with neurodevelopmental disabilities.

“There are many challenges associated with conducting pediatric clinical trials, from patient enrollment to medication adherence to operational procedures that need to be tailored to meet the needs of children. We believe that using the right technology can help us increase efficiencies and overcome many of these challenges, which is why we’ve turned to Medidata,” says Shigeki Shimasaki, head of research and development at Nobelpharma, in a release. “With Medidata’s innovative technology, we can make our research processes more efficient, so that we can focus on speeding up the development and delivery of new therapies for children with very serious diseases and limited treatment options.”

To increase the speed and quality of its clinical research programs, Nobelpharma is utilizing Medidata’s unified solutions for electronic data capture (EDC), management and reporting solution (Medidata Rave); medical coding (Medidata Coder); randomization (Medidata Balance) and electronic patient-reported outcomes (Medidata Patient Cloud). CMIC, a Japanese contract research organization (CRO) and a long-term Medidata partner, will help Nobelpharma implement the technology and also provide clinical monitoring and data management services for the sleep disorder study.

Nobelpharma is also using patient recruitment service CROèe’s medication adherence app for the trial. The app is designed to help increase adherence by helping children manage stress associated with changes in their routine.

“Nobelpharma’s work developing pharmaceuticals and medical devices for small populations of patients with difficult-to-treat diseases is critically important,” says Takeru Yamamoto, Medidata’s managing director of Japan. “We share their commitment to innovation and are proud that our technology platform is furthering Nobelpharma’s and a growing number of life science organizations’ efforts to bring innovative new treatments to patients with greater speed and precision.”